Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Pharmacol Res. 2019 May 6;145:104263. doi: 10.1016/j.phrs.2019.104263

Figure 1. Effect of olaparib on lung, liver and spleen MPO and MDA levels in young male Balb/c mice subjected to CLP.

Figure 1.

(A): Lung, liver and spleen MPO levels (expressed as milliunits [mU]/gram tissue) and (B): lung, liver and spleen MDA levels (expressed as μM/gram tissue) are shown in sham mice (not subjected to CLP) (“Sham”), in vehicle-treated mice subjected to CLP for 24 hours (“CLP”) and in mice subjected to CLP in the presence of various doses of olaparib (“CLP Olaparib 1 mg/kg”, CLP Olaparib 3 mg/kg” and “CLP Olaparib 10 mg/kg”). Data are shown as mean ± SEM of 10 animals for each group; *p<0.05 shows significant increase in MPO in response to CLP, compared to the sham group; #p<0.05 shows significant protective effect of olaparib in CLP mice compared to vehicle-treated CLP mice.